Table 1.

Experimental data obtained with primary MM samples, and general patient characteristics

Experiments
Patient characteristics
Percent viable cells
Treatment
Culture with IL-6
Culture with BMSCs
Age
Sex
Stage
Immunoglobulin type
Prior chemotherapy
Patient no. 1    58   Male   III A   IgA (lambda)   AD, HDT-M  
   Control   62   67       
   PD98059   46   52       
   Sant7   36   58       
   PD98059 + Sant7   18   25       
Patient no. 2    70   Male   III A   Light chain(lambda)   VAD  
   Control   60   63       
   PD98059   50   54       
   Sant7   42   58       
   PD98059 + Sant7   33   35       
Patient no. 3    50   Male   III A   IgG (lambda)   VAD, MP  
   Control   71   67       
   PD98059   44   44       
   Sant7   38   52       
   PD98059 + Sant7   14   13       
Patient no. 4    57   Female   III A   IgG (kappa)   VAD,  
   Control   62   67       
   PD98059   48   57       VBAM + D, HDT-M  
   Sant7   38   56       
   PD98059 + Sant7   17   22       
Patient no. 5    59   Male   III A   IgG (lambda)   No  
   Control   75   78       
   PD98059   57   66       (new diagnosis)  
   Sant7   25   76       
   PD98059 + Sant7   12   13       
Patient no. 6    58   Male   II A   IgA (lambda)   No  
   Control   70   72       
   PD98059   47   49       
   Sant7   26   68       
   PD98059 + Sant7   10   19       
Patient no. 7    78   Male   I A   IgA + IgG (kappa)   No  
   Control   77   87       
   PD98059   41   51       
   Sant7   42   74       
   PD98059 + Sant7   19   49       
Patient no. 8    54   Female   III A   Light chain (kappa)   ID,  
   Control   50   51       
   PD98059   50   51       Tandem HDT-M  
   Sant7   32   52       
   PD98059 + Sant7   16   21       
Patient no. 9    75   Male   III B   IgA (kappa)   MP, D, Thal  
   Control   90   93       
   PD98059   89   92       
   Sant7   20   90       
   PD98059 + Sant7   7   14       
Patient no. 10    49   Male   III A   IgG (kappa)   VAD  
   Control   50   55       
   PD98059   42   41       
   Sant7   23   53       
   PD98059 + Sant7   13   15       
Patient no. 11    56   Female   III A   Nonsecreting   VAD, D  
   Control   71   69       
   PD98059   48   52       
   Sant7   19   53       
   PD98059 + Sant7
 		 9
 		 11
 
 
 
 
 
 
Experiments
Patient characteristics
Percent viable cells
Treatment
Culture with IL-6
Culture with BMSCs
Age
Sex
Stage
Immunoglobulin type
Prior chemotherapy
Patient no. 1    58   Male   III A   IgA (lambda)   AD, HDT-M  
   Control   62   67       
   PD98059   46   52       
   Sant7   36   58       
   PD98059 + Sant7   18   25       
Patient no. 2    70   Male   III A   Light chain(lambda)   VAD  
   Control   60   63       
   PD98059   50   54       
   Sant7   42   58       
   PD98059 + Sant7   33   35       
Patient no. 3    50   Male   III A   IgG (lambda)   VAD, MP  
   Control   71   67       
   PD98059   44   44       
   Sant7   38   52       
   PD98059 + Sant7   14   13       
Patient no. 4    57   Female   III A   IgG (kappa)   VAD,  
   Control   62   67       
   PD98059   48   57       VBAM + D, HDT-M  
   Sant7   38   56       
   PD98059 + Sant7   17   22       
Patient no. 5    59   Male   III A   IgG (lambda)   No  
   Control   75   78       
   PD98059   57   66       (new diagnosis)  
   Sant7   25   76       
   PD98059 + Sant7   12   13       
Patient no. 6    58   Male   II A   IgA (lambda)   No  
   Control   70   72       
   PD98059   47   49       
   Sant7   26   68       
   PD98059 + Sant7   10   19       
Patient no. 7    78   Male   I A   IgA + IgG (kappa)   No  
   Control   77   87       
   PD98059   41   51       
   Sant7   42   74       
   PD98059 + Sant7   19   49       
Patient no. 8    54   Female   III A   Light chain (kappa)   ID,  
   Control   50   51       
   PD98059   50   51       Tandem HDT-M  
   Sant7   32   52       
   PD98059 + Sant7   16   21       
Patient no. 9    75   Male   III B   IgA (kappa)   MP, D, Thal  
   Control   90   93       
   PD98059   89   92       
   Sant7   20   90       
   PD98059 + Sant7   7   14       
Patient no. 10    49   Male   III A   IgG (kappa)   VAD  
   Control   50   55       
   PD98059   42   41       
   Sant7   23   53       
   PD98059 + Sant7   13   15       
Patient no. 11    56   Female   III A   Nonsecreting   VAD, D  
   Control   71   69       
   PD98059   48   52       
   Sant7   19   53       
   PD98059 + Sant7
 		 9
 		 11
 
 
 
 
 
 

Overview of the individual responses of primary myeloma cells to treatment with PD98059 (50 μM) and/or Sant7 (50 μg/mL). The numbers represent the percentage of viable cells after treatment with the respective drug or drugs. Myeloma cell preparations from 11 patients were kept either in medium supplemented with 2 ng/mL IL-6, or in coculture with primary BMSCs, and were assayed for apoptosis after 5 to 7 days. Some general information regarding the patients and their treatment is included.

VAD indicates vincristine, doxorubicine, dexamethasone; MP, melphalan, prednisone; D, dexamethasone; VBAM, vincristine, bendamustine, doxorubicine, melphalan; ID, idarubicine, dexamethasone; HDT-M, high-dose therapy melphalan; Thal, thalidomide.

View Large